Is A or BIAF more undervalued in 2026?

CirclFi compares Agilent Technologies, Inc. (A) and bioAffinity Technologies, Inc. (BIAF) using 13 institutional-grade valuation models. A has a Quality of Company score of 9.5/10 while BIAF scores 4.7/10.

Which is a better buy — A or BIAF?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do A and BIAF valuations compare?

A at $135.38 and BIAF at $1.65 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

A vs BIAF Valuation Comparison 2026 — Intrinsic Value Analysis

A

Diagnostics & Research

Agilent Technologies, Inc.

Quality

9.5

out of 10

Value Trap

SAFE

Price

$135.38

Last close

Models

13/13

Active

BIAF

Diagnostics & Research

bioAffinity Technologies, Inc.

Quality

4.7

out of 10

Value Trap

WARN

Price

$1.65

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	A Fair Value	A Upside	BIAF Fair Value	BIAF Upside
Bayesian DCF	Intrinsic	$72.69	-46.3%	$0.71	-56.7%
Earnings Power Value	Intrinsic	$32.33	-76.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$96.77	-28.5%	$0.18	-91.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for A vs BIAF — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

A vs BIAF — Which Stock Is More Undervalued?

A scores higher with a 9.5/10 quality rating vs BIAF's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Agilent Technologies, Inc. (A) and bioAffinity Technologies, Inc. (BIAF) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

A currently trades at $135.38 with a QOC of 9.5/10, while BIAF trades at $1.65 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).